Aviragen Therapeutics (AVIR) Reports Q4 Loss of $0.15/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
August 31, 2017 4:01 PM EDTATLANTA, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ: AVIR) today announced its financial results for the three months and fiscal year ended June 30, 2017.
We have made great strides, working with our Board and financial advisors, in honing in on a select number of strategic alternatives, commented Joseph M. Patti, PhD, President and Chief Executive Officer of Aviragen Therapeutics. Importantly, we have also taken actions to minimize cash spending in order to maintain the Companys solid financial position as evidenced by our reported cash position of $38.6 million.
... More